No annual revenue total was found in ARRIVENT BIOPHARMA, INC.'s SEC filings.
Arrivent Biopharma, Inc. (AVBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $373.1 million in cash and investments and $351,000 in total debt.
Revenue
—
Net income (TTM)
$-163.74M
-19.5% vs year-ago TTM
Operating cash flow (TTM)
$-147.93M
-16.8% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-3.69
+8.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
44.20M
+29.9% vs prior year
Net cash
$372.77M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown Square, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1868279
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$177.5M | -$94.3M |
| Net income | -$166.3M | -$80.5M |
| Diluted EPS | -$4.32 | -$2.56 |
| Operating cash flow | -$160.6M | -$70.2M |
| Total assets | $333.2M | $274.9M |
| Total liabilities | $25.9M | $17.3M |
| Stockholders' equity | $307.2M | $257.7M |
| Cash and investments | $312.8M | $266.5M |
| Total debt | $14,000 | $176,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Results of operations
|
Aug 12, 2026 | Aug 11, 2026 |
All 160 Arrivent Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.